Roll

Roll Therapeutics was a biotechnology company focused on developing small molecule drugs to regulate the activity of the immune and nervous systems. The company's primary research centered on mitochondrial dynamics, specifically targeting the Dynamin-related protein 1 (Drp1) to inhibit mitochondrial fission associated with neurodegeneration and inflammation. Founded by experienced biotech entrepreneurs, the firm aimed to address high-unmet-need conditions such as Multiple Sclerosis and Parkinson's Disease. Although it operated in a semi-stealth mode with venture backing, the company appears to have ceased active operations in recent years.